Strs Ohio Sells 15,559 Shares of Edwards Lifesciences Corp (NYSE:EW)

Strs Ohio lowered its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 319,833 shares of the medical research company’s stock after selling 15,559 shares during the quarter. Strs Ohio’s holdings in Edwards Lifesciences were worth $70,334,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. TRUE Private Wealth Advisors bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $26,000. Evolution Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the 2nd quarter worth about $29,000. M&R Capital Management Inc. bought a new position in Edwards Lifesciences during the 2nd quarter worth about $29,000. Next Capital Management LLC grew its holdings in Edwards Lifesciences by 297.7% during the 2nd quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock worth $32,000 after acquiring an additional 128 shares in the last quarter. Finally, Tarbox Family Office Inc. grew its holdings in Edwards Lifesciences by 48.7% during the 2nd quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock worth $33,000 after acquiring an additional 58 shares in the last quarter. 81.75% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Robert W.A. Sellers sold 17,417 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $211.57, for a total transaction of $3,684,914.69. Following the completion of the transaction, the vice president now directly owns 23,655 shares of the company’s stock, valued at $5,004,688.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 21,000 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $211.92, for a total value of $4,450,320.00. Following the transaction, the vice president now directly owns 41,713 shares of the company’s stock, valued at $8,839,818.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 154,670 shares of company stock worth $33,420,945. 1.63% of the stock is currently owned by corporate insiders.

A number of research firms have recently weighed in on EW. Jefferies Financial Group raised their price target on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. ValuEngine cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Bank of America reissued a “buy” rating and issued a $225.00 price target (up previously from $215.00) on shares of Edwards Lifesciences in a research note on Wednesday, July 24th. Finally, Barclays lifted their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research note on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. Edwards Lifesciences has a consensus rating of “Buy” and a consensus price target of $219.06.

EW traded down $1.27 on Monday, hitting $226.19. 169,609 shares of the company’s stock were exchanged, compared to its average volume of 1,185,341. Edwards Lifesciences Corp has a fifty-two week low of $136.44 and a fifty-two week high of $230.19. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $221.73 and a 200-day moving average price of $198.64. The stock has a market cap of $47.38 billion, a price-to-earnings ratio of 48.13, a P/E/G ratio of 2.87 and a beta of 0.84.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company posted $1.24 EPS. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Corp will post 5.33 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Return on Investment (ROI) Defined, Explained

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.